Former Israeli Military Officer Leads AI-Driven Biotech Startup Incubator with Nine Ventures Founded

A 47-year-old Israeli CEO of AION Labs, a biotech startup incubator, shares his journey from Ohio to leading innovation in Israel. Born into a conservative Jewish family in Ohio, he immigrated to Israel at age 12, quickly feeling a strong sense of belonging. Despite a childhood baseball injury causing partial blindness, he enlisted in the Israeli Defense Forces at 16, serving in the Foreign Relations Division coordinating with the Jordanian army and UN forces, and participated in planning joint air defense during the Gulf War. He left the army as a captain at 24.

After military service, he studied law and became involved in youth leadership and legal organizations. He worked closely with former Shin Bet chief Avi Dichter during his political campaign and later served as his personal aide. During the 2006 Lebanon War, he was wounded near the Gaza border by gunfire but recovered and reprioritized his life toward family and health.

Transitioning to the private sector, he joined Teva Pharmaceuticals as a legal intern and quickly advanced to COO of the legal department. He led efforts to reform Israeli tax law to better support research and development. Despite initial skepticism from Teva’s CEO regarding investing in Israeli pharmaceutical innovation, he successfully advocated for continued investment.

In 2019, he helped establish AION Labs to harness artificial intelligence for drug development, winning government support and venture capital funding. By 2021, AION Labs became an independent company with partnerships including Teva, Merck, Pfizer, and AstraZeneca. Under his leadership, the incubator has launched nine startups, with a third securing follow-on funding ranging from $1 million to $10 million. One startup, Combinable, was acquired by Insitro. The incubator is now exploring quantum computing applications in drug development.

He emphasizes the importance of leadership skills over scientific background for managing the coalition of pharmaceutical partners and aims to continue advancing AI and quantum technologies in biotech.